Test reveals COVID-19 patients at risk for severe illness

By LabPulse.com staff writers

September 10, 2020 -- A new test for SARS-CoV-2 viral proteins may help identify COVID-19 patients most at risk for becoming critically ill, according to a study published September 8 in Clinical Chemistry.

The single-molecule array Simoa SARS-CoV-2 antigen test is the first to detect and measure blood levels of S1, a protein that is part of the viral envelope of the novel coronavirus. Identifying patients most susceptible to severe complications may help healthcare workers better manage these patients and ensure that space is available at intensive care units (ICUs), according to the study.

Researchers at Brigham and Women's Hospital and Harvard University, who developed the test, evaluated its performance on 64 patients who tested positive for COVID-19 via standard diagnostic polymerase chain reaction (PCR) tests.

The patients had the following S1 levels:

  • 23 had undetectable concentrations.
  • 23 had low concentrations of 6 pg/mL to 50 pg/mL.
  • 18 had high concentrations that were greater than 50 pg/mL.

The researchers found a link between high concentrations of S1 and admissions to ICUs. In all, 77% of those with high concentrations were admitted to the ICU and required intubation within one day of coming to the hospital. What's more, 52% of patients with low concentrations needed intensive care, and only 30% of those with undetectable levels were admitted to the ICU, according to the results.

FDA grants DetectaChem EUA for mobile COVID-19 test
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to DetectaChem for its mobile COVID-19 test kit.
Experts draw lessons from FDA's hydroxychloroquine EUA controversy
Public health and regulatory experts advocated for changes to the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) process in...
Maxim Biomedical on track to make 3M COVID-19 tests
Maxim Biomedical plans to produce and market as many as 3 million Maxim SARS-CoV-2 rapid antigen diagnostic tests by the end of the year.
Detecting SARS-CoV-2 in blood may be early indicator of severe disease
A blood test that measures SARS-CoV-2 RNA when patients are admitted to the hospital with COVID-19 symptoms can be a powerful diagnostic tool to predict...
NIH to spend $129M to scale up COVID-19 testing
The U.S. National Institutes of Health (NIH) plans to spend about $129 million to scale up COVID-19 testing capacity and provide manufacturing support....

Copyright © 2020 LabPulse.com

Last Updated np 9/10/2020 8:34:53 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current